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~ Reduction of tumor necrosis factor alpha (TNF~) expression by 
azithromycin (AZM) in CF airway epithelial cells 
C. Cigana, E. Nicolis, B.M. Assael, R Melotti. Cystic Fibrosis Cente~ Azienda 
Ospedaliera di Verona, Italy 
AZM has been described to ameliorate airway inflammation in CF patients. We 
aimed to study properties of this macrolide relevant for therapy, in particular anti- 
inflammatory effects. 
Since TNFo. plays a relevant role in pathogenesis of  CF as pro-inflammatory 
molecule, we compared its levels of mRNA and protein expression, by QPCR 
and ELISA, in two CF airway epithelial cell lines. 
Cells were incubated with AZM or josamycin (JM), a macrolide lacking clinical 
anti-inflammatory effects. Activation of  pro-inflammatory transcription factors (TF) 
involved in the regulation of TNFo. transcription as Nuclear Factor-kB (NF-kB) 
and Specificity protein 1 (Spl) was determined by immunofluorescent staining in 
untreated cells and in the presence of AZM. 
We found that AZM reduces the levels of TNFo. mRNA in both cell lines (about 
30%, p < 0.01) as well as TNFo. protein levels (about 55%, p < 0.01) compared to 
untreated cells, while JM was not significantly effective. Nuclear staining of NFkB 
and Spl was reduced in the presence of AZM in comparison with untreated cells. 
In an isogenic non-CF cell line we detected statistically significantly lower levels 
of TNFo. compared to the CF line, specifically supporting the therapeutic relevance 
of our data. 
Our study demonstrates that AZM reduces the expression of TNFo. mRNA and 
protein and suggests the inhibition of nuclear localization of NF-kB and Spl as 
a possible mechanism. Consistent with our previous detection of inhibition of 
interleukin 8 expression by AZM, the results of the present study further support 
the proposed anti-inflammatory effects of this macrolide relevant for therapy of  CE 
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3. New therapies' 
[~] Effects of glargine insulin in patient with cystic fibrosis (CF) and 
impaired glucose tolerance (IGT) 
R Ciampalini 1, C. Bizzarri 1 , S. Bella 2, B. Russo 2, M. Cappa 1 , V Lucidi 2. 
1Department of Paediatric Medicine: Unit of  Endocrinology, 2Unit of  Cystic 
Fibrosis', Bambino Ges~ Children ~' HosTital, Rome, Italy 
Diabetes mellitus is an increasing complication of CF, as a result of  the improved 
life expectancy. There is clear association between diabetes and increased morbidity 
and mortality. Lung function and nutritional status deteriorate 2 4 years before the 
diagnosis of cystic fibrosis related diabetes. Aim of  our study was to evaluate the 
effects of the early treatment with glargine insulin in CF patients with impaired 
glucose tolerance (IGT). We selected 6 patients with IGT diagnosed by oral 
glucose tolerance test. Median age was 18.12 yr. (9.2~7.8). Glargine insulin was 
administered atthe median dosage of  0.3 U/kg/day (0.2 0.5). No patient manifested 
hypoglycemia. Glycosylated haemoglobin (HbA1C) didn't show any significant 
variation during treatment. Median HbA1C was 5.9% at baseline (5.5 6.2) and 
6.1% (5.0 6.7) at the end of follow up (p: 0.496). Median BMI Z score significantly 
increased during insulin therapy, from 0.95 (3 .2±0.6)  at baseline, to 0.5. 
(3 .0±0.9)  at the end of follow up (p: 0.026). Lung function, measured by median 
FEV1% showed a mild improvement, from 72.7% at baseline (41.5 98.4) to 76.7% 
(42.0 106.8) at the end of follow up (p: 0.027). Our data seems to indicate that 
early insulin therapy can be safe. Insulin is an anabolic hormone implicated in both 
lipid and protein metabolism. The appearance of IGT out of infections can indicate 
an early insulin deficiency, with a potential impact on the nutritional and clinical 
status of the patient, before the appearance of overt diabetes. Larger controlled trials 
are necessary to verify if early insulin therapy is able to reduce the deterioration of  
clinical status associated with the onset of IG% 
• Novel in vivo anti-inflammatory action of azithromycin in 
CF subjects 
D.J. McKeon 1'2, C. Laughton 2, E. Gunn 2, K. Cadwallader 1 , J. Foweraker 2,
D. Bilton 2, E.R. Chilvers 1. 1Respiratory Division, Department of Medicine, 
University of Cambridge, Cambridge; 2papworth Adult CF Cente~ Papworth 
Hospital, Papworth, UK 
Aims: Azithromycin is a macrolide antibiotic with a well established role in the 
treatment of  CF lung disease. Its beneficial actions are thought o relate to its anti- 
inflammatory rather than its bacteriocidal properties, although a specific mechanism 
is yet to be determined. As oxidants contribute to host damage in the CF lung 
we hypothesized that the anti-inflammatory action of azithromycin may be due to 
inhibition of  the neutrophil respiratory burst. 
Methods: 10 stable adult CF subjects were recruited. All were colonized with 
Pseudomonas aeruginosa but clinically stable. Neutrophils were purified from 
peripheral blood before and after commencement of azithromycin therapy (250 rag, 
three times/week) using plasma/Percoll gradients. Oxidant production was measured 
using chemiluminesence (CL) and lucigenin (Luci-DCL) or luminol (Lum-DCL) 
under the following conditions: GM-CSF (100ng/ml, 30min), fMLP (100nM) or 
PMA (1 ng/ml).alone, or GM-CSF followed by fMLR 
Results: 7 subjects completed the study. Mean time on treatment was 6 months 
(range 2 14 months). For all conditions oxidant production measured by both Luc- 
DCL and Lum-DCL was significantly reduced (p < 0.005, Mann Whitney test) in 
CF subjects established on azithromycin. 
Conclusion: This is the first study to report he effects of azithromycin on neutrophil 
oxidant production in CF subjects. These results suggest hat azithromycin reduces 
the ability of CF neutrophil's to produce oxidants and may represent one of its key 
anti-inflammatory actions. 
Nebulisation of a novel Pseudomonas aeruginosa biofilm 
formation inhibiting sensing blocker by the eFIow ~ electronic 
nebuliser 
M. Tservistas 1 , A. Gotschlich 2, A. Bucholski 1 , M. Keller 1 . 1PARI GmbH, Aerosol Research 
Institute, Steinerst~ 15c, Munich; 24SC ACT, Am Klopferspitz 19 A, 82152 Martinsried, Germany 
Ahn: 4SC developed a novel Quorum Sensing Blocker (QSB) against biofilm forming bacterias, 
such as/? aeruginosa and R cepacia. We investigated if experimental aqueous formulations can be 
nebttlised by eFlow ® a very efficient electronic nebttliser. 
Experimental: Ti~ree different concentratioi~s of QSB (25, 50 and 100mg/nfl) were prepared 
in isotonic saline solution. Without additional excipients two-phase systems (liquid/liquid) were 
obtained for all concentrations. These were dispersed to form emttlsioi~s prior to nebulization by 
an eFlow ® 35L coikfiguration (PARI GmbH, Germany). While strong foam formation was observed 
at 100 mg/nfl, concentratioi~s of 25 and 50 mg/nfl could be nebulized without foam formation. For 
these concentrations the aerosols were assessed by laser diffractometry (Mastersizer X, Malvern 
Instruments, Herrenberg, Germany). 
Results: Mass Median Diameter (MMD), Geometric Standard Deviation (GSD), Respirable Fraction 
(RF, % droplets <5~n) and the Total Output Rate (TOR) were investigated for each concentration in 
duplicate. 
25 mg/ml 50 mg/ml 
tun  1 tun  2 tun  1 tun  2 
MMD [~m] 3.84 3.93 4.01 4.10 
GSD 1.63 1.64 1.65 1.65 
RF [%] 71 69 67 66 
TOR [lll~ 1~ 11] 581 588 638 521 
Similar aerosol characteristics were obtained for both concentrations, with MMD values from 
3.8 to 4.1 ~tm, narrow droplet size distributions (GSD around 1.65), high RF (66 71%) and output 
rates (521 to 638rag/rain) indicating short nebulisation times. 
Conclusions: Tiffs proof-of-principle study showed tl/at QSB can be nebulised up to 50 mg/ml. Further 
formulation developnlent is required to obtain stable hfl/alable QSB formulations which may offer 
new perspectives for the treatment ofbiofilm forming Gram-negative bacterias. 
